

CORRECTION OPEN



Correction: Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated *Listeria monocytogenes* in hepatobiliary cancers

Inga Hochnadel, Lisa Hoenicke , Nataliia Petriv, Lavinia Neubert, Elena Reinhard, Tatjana Hirsch, Juan Carlos Lopez Alfonso, Huizhen Suo, Thomas Longerich, Robert Geffers, Ralf Lichtinghagen, Carlos Alberto Guzmán, Heiner Wedemeyer, Henrike Lenzen, Michael Peter Manns, Dunja Bruder and Tetyana Yevsa

© The Author(s) 2022


Oncogene (2022) 41:2787; <https://doi.org/10.1038/s41388-022-02261-6>

Correction to: *Oncogene* <https://doi.org/10.1038/s41388-022-02222-z>, published online 16 February 2022

The graphic abstract was missing from this article and should have appeared as below.

Protective immune mechanism induced by live-attenuated double-deleted *L. monocytogenes* $\Delta actA/\Delta inlB$ vaccine strain delivering tumor antigens keeps hepatobiliary malignancies under control. Live-attenuated, double-deleted *L. monocytogenes* $\Delta actA/\Delta inlB$ strain expressing model tumor antigen was used in both, prophylactic and therapeutic vaccination settings. Vaccination was safe and led to: (i) induction of protective tumor-specific Th1 immune responses in premalignant and malignant stages and strong increase of tumor-specific IFN- γ^+ CD4 and CD8 T cells; (ii) decrease of T regulatory cells; (iii) downregulation of several tumor-promoting ICI molecules (PD-1, CD160, LAG3, 4-1BBL) on CD4/CD8 T lymphocytes; (iv) decrease of tumor-specific IgG in

serum, and (v) decrease of B lymphocytes, DC and M Φ locally in livers. iCCA, intrahepatic cholangiocarcinoma.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022